Login to Your Account

Denosumab Builds Bone Density, but Infection Concerns Emerge

By Donna Young

Friday, April 4, 2008
Amgen Inc.'s experimental osteoporosis drug, denosumab, met all bone mineral density (BMD) endpoints for all skeletal sites in a two-year, 332-patient Phase III study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription